Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2026)

Precision Biosciences (DTIL) has reported Change in Accured Expenses for 9 consecutive years, with -$1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 64.91% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at $1.6 million (up 210.72% YoY), while the FY2025 annual figure was -$1.8 million, up 17.2% from the prior year.
• Change in Accured Expenses declined to -$1.8 million in Q1 2026 per DTIL's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.4 million in Q2 2022 and bottomed at -$5.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$483882.4 across 5 years, with a median of $474000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 139.98% — and 2025, when it soared 1478.85%.
• Precision Biosciences' Change in Accured Expenses stood at $421000.0 in 2022, then soared by 464.61% to $2.4 million in 2023, then plunged by 106.56% to -$156000.0 in 2024, then jumped by 1478.85% to $2.2 million in 2025, then slumped by 183.5% to -$1.8 million in 2026.
• Business Quant data shows DTIL's Change in Accured Expenses at -$1.8 million in Q1 2026, $2.2 million in Q4 2025, and $528000.0 in Q3 2025.